Loading stock data…
$13.54-0.19 (-1.42%)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer.
Alpha Tau Medical Ltd. in the Healthcare sector is trading at $13.54 with a market capitalization of $1.3B. Wall Street consensus targets $17.80 (5 analysts), implying a +31.4% move over the next 12 months. The stock is currently near its 52-week high of $15.79, remaining 33.2% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$13.78M↓ | -$13.31M↓ | -$12.60M↓ | -$10.73M↓ | -$9.65M |
| Net Income | -$45.81M↓ | -$22.94M↓ | -$12.14M↓ | -$11.69M↓ | -$10.11M |
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technolog...